Ancillary Testing, Diagnostic/Classification Criteria and Severity Grading in Behçet Disease

REFERENCES

• Acikgoz N, Karincaoglu Y, Ermis N, et al. Increased mean platelet volume in Behçet’s disease with thrombotic tendency. Tohoku J Exp Med. 2010;221(2):119–123.
   PubMed Web of Science ®Google Scholar
• Kavala M, Menteş F, Kocaturk E, et al. Microalbuminuria as an early marker of renal involvement in Behçet’s disease: it is associated with neurological involvement and duration of the disease. J Eur Acad Dermatol. Venereol. 2010;24(7):840–843.
   PubMed Web of Science ®Google Scholar
• Iwata D, Namba K, Mizuchi K, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab. (Online first) Graefes Arch Clin Exp Ophthalmol. Jan 2012; DOI: 10.1007/s00417-011-1908-1.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet’s disease. Am J Ophthalmol. 2008;146(6):845–850.
   PubMed Web of Science ®Google Scholar
• Kera J, Mizuki N, Ota M, et al. Significant associations of HLA-B*5101 and B*5108, and lack of association of class II alleles with Behçet’s disease in Italian patients. Tissue Antigens. 1999;54(6):565–571.
   PubMedGoogle Scholar
• Mizuki N, Ohno S, Ando H, et al. A strong association between HLA-B*5101 and Behçet’s disease in Greek patients. Tissue Antigens. 1997;50(1):57–60.
   PubMedGoogle Scholar
• Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. New Engl J Med. 1999;341:1284–1291.
   PubMed Web of Science ®Google Scholar
• Kartal Durmazlar SP, Akgul A, Eskioglu F. Homocysteine may involve in the pathogenesis of Behçet’s disease by inducing inflammation. Mediators Inflamm. 2008. Published online 2009 February 1. doi: 10.1155/2008/407972
   PubMed Web of Science ®Google Scholar
• Verity DH, Vaughan RW, Madanat W, et al. Factor V Leiden mutation is associated with ocular involvement in Behçet’s disease. Am J Ophthalmol. 1999;128(3):352–356.
   PubMed Web of Science ®Google Scholar
• Koçer N, Islak C, Siva A, et al. CNS involvement in neuro-Behçet syndrome: an MR study. AJNR Am J Neuroradiol. 1999;20(6):1015–1024.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–1250.
   PubMed Web of Science ®Google Scholar
• Bozzoni-Pantaleoni F, Gharbiya M, Pirraglia MP, Accorinti M, Pivetti-Pezzi P. Indocyanine green angiographic findings in Behçet disease. Retina. 2001;21(3):230–236.
   PubMed Web of Science ®Google Scholar
• Klaeger AJ, Tran VT, Hiroz CA, Morisod L, Herbort CP. Use of ultrasound biomicroscopy, indocyanine green angiography and HLA-B51 testing as adjunct methods in the appraisal of Behçet’s uveitis. Int Ophthalmol. 2004;25(1):57–63.
   PubMedGoogle Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu, Kir N, Urgancioglu M. Neovascularization of the optic disc in Behçet’s disease. Jpn J Ophthalmol. 2006;50:256–265.
   PubMed Web of Science ®Google Scholar
• Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Behcet disease. Ocul Immunol Inflamm. 2009;17:41–46.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Sato Y, Shiraga F, Shiragami C, Tsuchida Y. Choroidal abnormalities in Behçet disease observed by simultaneous indocyanine green and fluorescein angiography with scanning laser ophthalmoscopy. Ophthalmology. 1999;106(2):295–300.
   PubMed Web of Science ®Google Scholar
• Gedik S, Akova Y, Yilmaz G, Boazbeyoğlu S. Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Behcet’s disease. Ocul Immunol Inflamm. 2005;13(1):51–58.
   PubMed Web of Science ®Google Scholar
• Atmaca LS, Batioğlu F. Indocyanine green videoangiography and color Doppler imaging in Behçet’s disease. Acta Ophthalmol Scand. 1999;77(4):444–447.
   PubMedGoogle Scholar
• Tugal-Tutkun I, Cingü K, Kir N, Yeniad B, Urgancioglu M, Gül A. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246(8):1169–1177.
   PubMed Web of Science ®Google Scholar
• Cruz RD, Adachi-Usami E, Kakisu Y. Flash electroretinograms and pattern visually-evoked cortical potentials in Behçet’s disease. Jpn J Ophthalmol. 1990;34:142–148.
   PubMed Web of Science ®Google Scholar
• Hatt M, Niemeyer G. Elecroretinography in connection with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 1976;198:113–120.
   Google Scholar
• Chavis PS, Tabbara KF. Demyelination of retinal myelinated nerve fibers in Behçet’s disease. Doc Ophthalmol. 1998;95:157–164.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Chams-Davatchi C, Ghodsi Z, et al. Diagnostic value of pathergy test in Behçet’s disease according to the change of incidence over the time. Clin Rheumatol. 2011;30(9):1151–1155.
   PubMed Web of Science ®Google Scholar
• Hatemi I, Hatemi G, Celik AF, et al. Frequency of pathergy phenomenon and other features of Behçet’s syndrome among patients with inflammatory bowel disease. Clin Exp Rheumatol. 2008;26(4 Suppl 50):591–595.
   Web of Science ®Google Scholar
• Mason RM, Barnes CG. Behçet’s syndrome with arthritis. Ann Rheum Dis. 1969;28:95–103.
   PubMed Web of Science ®Google Scholar
• O’Duffy JD, Goldstein NP. Neurologic involvement in seven patients with Behçet’s disease. Am J Med. 1976;61:170–178.
   PubMed Web of Science ®Google Scholar
• Behçet’s Disease Research Committee of Japan. Behçet’s disease: a guide to diagnosis of Behçet’s disease. Jpn J Ophthalmol. 1974;18:291–294.
   Google Scholar
• Mizushima Y, Inaba G, Mimura Y, Ohno S, Matsuda T. Guide for the diagnosis of Behçet disease [in Japanese]. Report of Behçet Disease Research Committee, p. 16, Ministry of Health and Welfare, Japan, 1987.
   Google Scholar
• Zhang Z-Q (in Chinese). Chin J Intern Med. 1980;19:15–20.
   PubMedGoogle Scholar
• Dilsen N, Konice M, Aral O. Our diagnostic criteria for Behçet’s disease—an overview. In: Lehner T, Barnes CG, eds. Recent Advances in Behçet’s Disease. Int Congre Ser. 103:177–180, 1986.
   Google Scholar
• Dilsen N, Konice M, Aral O. Our diagnostic criteria for Behçet’s disease. In: Hamza M, ed. Behçet’s Disease: Proceedings of the 3rd Mediterranean Congress of Rheumatology, May 1986, pp. 11–15, 1988.
   Google Scholar
• International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080.
   PubMed Web of Science ®Google Scholar
• Kaburaki T, Araki F, Takamoto M, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease. Graefe’s Arch Clin Exp Ophthalmol. 2010;248:709–714.
   PubMed Web of Science ®Google Scholar
• Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. Behçet’s disease in Japan: ophthalmological aspects. Trans Am Ophthalmol Soc. 1979;77:225–279.
   PubMedGoogle Scholar
• Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behçet’s disease with ocular involvement. Graefe’s Arch Clin Exp Ophthalmol. 2005;243:1147–1152.
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Hakan Durukan A, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventionalm treatments. Ophthalmology. 2010;117:1430–1435.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazakoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose escalating interferon alpha 2a therapy in refractory Behçet’s uveitis. Arch Ophthalmol. 2011;129:288–294.
   PubMed Web of Science ®Google Scholar
• Dumonde DC, Kasp E, Graham E, et al. Anti-retinal autoimmunity and circulating immune complexes in patients with retinal vasculitis. Lancet. 1982;8302:787–792.
   Google Scholar
• Ben Ezra D, Forrester JV, Nussenblatt RB, et al. Uveitis Scoring System. Berlin: Springer Verlag; 1991.
   Google Scholar
• Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–431.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon alpha treatment inb patients with severe uveitis due to Behçet’s disease. Arth Rheum. 2010;62:2796–2805.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Herbort CP, Khairallah M, Mantovani A. Interobserver agreement in scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation. Ocul Immunol Inflamm. 2010;18(5):385–389.
   PubMed Web of Science ®Google Scholar